Cargando…
A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
Piritrexim is a lipid-soluble drug which is as effective an inhibitor of dihydrofolate reductase as methotrexate. Phase I and II studies have indicated activity in some tumour types. Because of its lipophilicity we have conducted a phase II study in recurrent high-grade malignant glioma (grades III...
Autores principales: | Bleehen, N. M., Newman, H. V., Rampling, R. P., Ramsay, J. R., Roberts, J. T., Bedford, P., Nethersell, A. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033879/ https://www.ncbi.nlm.nih.gov/pubmed/7669591 |
Ejemplares similares
-
Oral piritrexim, an effective treatment for metastatic urothelial cancer.
por: de Wit, R., et al.
Publicado: (1993) -
A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
por: de Vries, E. G., et al.
Publicado: (1993) -
Radiotherapy in high grade gliomas
por: Bleehen, N.M., et al.
Publicado: (1989) -
Facing Contrast-Enhancing Gliomas: Perfusion MRI in Grade III and Grade IV Gliomas according to Tumor Area
por: Di Stefano, Anna Luisa, et al.
Publicado: (2014) -
Bevacizumab in recurrent WHO grades II–III glioma
por: Annakib, Soufyan, et al.
Publicado: (2023)